Pharmanovia
Pharmanovia, a leading pharmaceutical company headquartered in Great Britain, has established itself as a key player in the global healthcare landscape since its founding in 2015. With a focus on specialty pharmaceuticals, the company operates across Europe, the Middle East, and Africa, delivering innovative solutions that address unmet medical needs. Pharmanovia's core offerings include a diverse portfolio of products in therapeutic areas such as oncology, neurology, and rare diseases. What sets Pharmanovia apart is its commitment to enhancing patient access to high-quality medicines through strategic partnerships and a robust supply chain. The company has achieved notable milestones, including the successful launch of several proprietary products, solidifying its market position as a trusted provider in the pharmaceutical industry.
DitchCarbon Score
How does Pharmanovia's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Pharmanovia's score of 27 is lower than 64% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Pharmanovia's reported carbon emissions
In 2023, Pharmanovia reported total carbon emissions of approximately 15,827,000 kg CO2e. This figure includes 60,000 kg CO2e from Scope 1 emissions and 4,493,000 kg CO2e from Scope 3 emissions, with a significant portion of the latter attributed to upstream transportation and distribution, which accounted for about 2,995,730 kg CO2e. Comparatively, in 2022, the company recorded total emissions of about 12,477,000 kg CO2e, comprising 60,000 kg CO2e in Scope 1, 3,000 kg CO2e in Scope 2, and 3,172,000 kg CO2e in Scope 3. The 2021 emissions were approximately 10,125,000 kg CO2e, with 51,000 kg CO2e in Scope 1, 76,000 kg CO2e in Scope 2, and a substantial 9,998,000 kg CO2e in Scope 3. Pharmanovia has not set specific reduction targets or initiatives as part of their climate commitments, nor do they participate in initiatives such as the Science Based Targets initiative (SBTi). The emissions data is not cascaded from any parent organization, indicating that these figures are solely from Pharmanovia itself. Overall, Pharmanovia's emissions have shown an upward trend over the past three years, highlighting the need for enhanced climate strategies and commitments to reduce their carbon footprint in the pharmaceutical industry.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | 2023 | |
|---|---|---|---|
| Scope 1 | 51,000 | 00,000 | 00,000 |
| Scope 2 | 76,000 | 0,000 | - |
| Scope 3 | 9,998,000 | 0,000,000 | 0,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Pharmanovia is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
